Clinical Trials Browser

Interventional × Borderline Resectable Pancreatic Cancer × irinotecan sucrosofate × Clear all

NCT06345300 2024-04-03

NALIRIFOX in Combination With Camrelizumab for BRPC: a Prospective, Exploratory Study

Phase 2 Unknown

Gastrointestinal

Borderline Resectable Pancreatic Cancer